Deutsche Bank Maintains a 'Buy' on Gilead Sciences (GILD); Weekly Scripts Tracking Ahead of Estimates

Deutsche Bank maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $57.00.

Analyst, Robyn Karnauskas, said, "Analysis of IMS Weekly scripts for the week 13 of 2Q:12 (week 13 of 13) indicates that GILD’s HIV franchise at $1,097.8M is tracking $32.9M better than consensus ($1,064.9M)...Ex all price increases in 1Q, we project sales would be tracking to $1,092.8M or about $28.0M better than consensus (DB analysis and FactSet). Notably, Complera projected Q2 sales are $18.5M better than consensus with Atripla & Truvada also tracking better than consensus."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $50.96 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• UBS Reiterates Buy Rating on HF Sinclair (DINO)